Table of Contents

1. OVERVIEW OF TREATMENTS FOR BENIGN UTERINE CONDITIONS… 1-1
1.1 Dilation and Curettage…………………………………………………………….. 1-3
1.1.1 Procedure Volumes………………………………………………….. 1-4
1.2 Hysterectomy…………………………………………………………………………. 1-5
1.2.1 Procedure Volumes………………………………………………….. 1-8
1.3 Hysteroscopy…………………………………………………………………………. 1-9
1.3.1 Endometrial Ablation ………………………………………………. 1-12
1.3.2 Procedure Volumes………………………………………………… 1-14
1.4 Myomectomy ……………………………………………………………………….. 1-16
1.4.1 Procedure Volumes………………………………………………… 1-17
Exhibit 1-1: Dilation and Curettage, Procedure Volumes Forecast, 2012-2017 … 1-6
Exhibit 1-2: Hysterectomy, Procedure Volumes Forecast, 2012-2017 …………… 1-11
Exhibit 1-3: Hysteroscopy, Procedure Volumes Forecast, 2012-2017 …………… 1-15
Exhibit 1-4: Myomectomy, Procedure Volumes Forecast, 2012-2017……………. 1-19
2. GLOBAL ENDOMETRIAL ABLATION DEVICES………………………………… 2-1
2.1 Selected Products ………………………………………………………………….. 2-2
2.1.1 Boston Scientific………………………………………………………. 2-2
2.1.2 CooperSurgical/The Cooper Companies……………………… 2-4
2.1.3 Ethicon/Johnson & Johnson………………………………………. 2-6
2.1.4 Hologic …………………………………………………………………… 2-8
Exhibit 2-1: 2013, Leading Global Endometrial Ablation Products ………………….. 2-3
Exhibit 2-2: Three-Step Endometrial Ablation Using the Genesys Hydro
ThermAblator System……………………………………………………………… 2-5
Exhibit 2-3: The Her Option Cryoablation System………………………………………… 2-7
Exhibit 2-4: The Gynecare ThermaChoice III Uterine Balloon Therapy System
in Comparison with Other Thermal Ablation Systems ………………….. 2-9
Exhibit 2-5: The NovaSure System and Step-by-Step Endometrial ……………………..
Ablation Process…………………………………………………………………… 2-11
Exhibit 2-6: Selected Features of the Next-Generation NovaSure System …….. 2-12
3. MAGNETIC RESONANCE-GUIDED HIGH-INTENSITY FOCUSED
ULTRASOUND SYSTEMS……………………………………………………………….. 3-1
3.1 Products and Procedure………………………………………………………….. 3-2
3.1.1 InSightec ………………………………………………………………… 3-4
3.1.1.1 Clinical Trials…………………………………………….. 3-8
3.1.2 Philips Healthcare/Royal Philips Electronics ………………… 3-9
3.1.2.1 Clinical Trials…………………………………………… 3-10
Exhibit 3-1: Simple Schematic Illustration of Focused Thermal
Energy Technology…………………………………………………………………. 3-3
Exhibit 3-2: Uterine Fibroid Treatment Using the ExAblate System ………………… 3-7
Exhibit 3-3: Sonalleve Therapy………………………………………………………………… 3-12
4. UTERINE ARTERY EMBOLIZATION SYSTEMS ………………………………… 4-1
4.1 Selected Products ………………………………………………………………….. 4-2
4.1.1 Biocompatibles/BTG International………………………………. 4-3
4.1.2 Boston Scientific………………………………………………………. 4-5
4.1.3 CeloNova BioSciences……………………………………………… 4-6
4.1.4 Merit Medical Systems ……………………………………………… 4-6
4.2 Embolization versus Focused Ultrasound for Fibroid Treatment ……. 4-8
Exhibit 4-1: 2013, Selected Embolic Agents Used in Uterine
Artery Embolization ………………………………………………………………… 4-4
Exhibit 4-2: CeloNova Biosciences’ Embozene Microspheres ……………………….. 4-7
Exhibit 4-3: Merit Medical Systems’ Embosphere Microspheres…………………….. 4-9
5. HYSTEROSCOPES AND RELATED PRODUCTS ………………………………. 5-1
5.1 Hysteroscopes and Fibroid Removal Systems ……………………………. 5-1
5.1.1 Ethicon/Johnson & Johnson………………………………………. 5-2
5.1.2 Gyrus ACMI/Olympus……………………………………………….. 5-7
5.1.3 Hologic …………………………………………………………………. 5-10
5.1.4 Olympus America/Olympus……………………………………… 5-13
5.1.5 Smith & Nephew…………………………………………………….. 5-15
5.1.6 KARL STORZ Endoscopy-America/KARL STORZ ……… 5-17
5.1.7 Stryker………………………………………………………………….. 5-23
5.1.8 Richard Wolf Medical Instruments/Richard Wolf …………. 5-23
5.2 Uterine Manipulators …………………………………………………………….. 5-26
5.2.1 ConMed………………………………………………………………… 5-26
5.2.2 Cook Medical/Cook Group ………………………………………. 5-28
5.2.3 Cooper Surgical/The Cooper Companies…………………… 5-28
5.3 Fluid Management Systems …………………………………………………… 5-28
5.3.1 Davol/C.R. Bard …………………………………………………….. 5-32
5.3.2 Gyrus ACMI/Olympus……………………………………………… 5-32
5.3.3 Hologic …………………………………………………………………. 5-35
5.3.4 Smith & Nephew…………………………………………………….. 5-35
5.3.5 Stryker………………………………………………………………….. 5-39
5.3.6 Richard Wolf Medical Instruments/Richard Wolf …………. 5-39
Exhibit 5-1: 2013, Selected Hysteroscopes and Hysteroscopy
Fibroid Removal Systems………………………………………………………… 5-3
Exhibit 5-2: The Gynecare Versapoint Bipolar Electrosurgery System…………….. 5-5
Exhibit 5-3: The Gynecare Morcellex Tissue Morcellator ………………………………. 5-6
Exhibit 5-4: The Gynecare Versascope Hysteroscopy System ………………………. 5-8
Exhibit 5-5: The PKS PlasmaSORD Bipolar Morcellator……………………………….. 5-9
Exhibit 5-6: The SlimLine Office and USA Series Continuous Flow
Operative Hysteroscopes ………………………………………………………. 5-11
Exhibit 5-7: The MyoSure Tissue Removal System ……………………………………. 5-14
Exhibit 5-8: The HYF-XP Flexible Hysteroscope………………………………………… 5-16
Exhibit 5-9: The Truclear Hysteroscopic Morcellator…………………………………… 5-18
Exhibit 5-10: The Bettocchi Integrated Office Hysteroscope ………………………….. 5-20
Exhibit 5-11: The Intra-Uterine Bigatti Shaver……………………………………………… 5-21
Exhibit 5-12: The Rotocut G1 Morcellator …………………………………………………… 5-22
Exhibit 5-13: The IDEAL EYES HD CST-5000S Flexible Video Hysteroscope …. 5-24
Exhibit 5-14: The OptiFLOW Single Sheath Hysteroscope ……………………………. 5-25
Exhibit 5-15: The BipoTrode Bipolar Electrode…………………………………………….. 5-27
Exhibit 5-16: The VCare Vaginal-Cervical Ahluwalia Retractor/Elevator………….. 5-29
Exhibit 5-17: The Uterine Manipulator Injector …………………………………………….. 5-30
Exhibit 5-18: The RUMI Advanced Uterine Manipulation System……………………. 5-31
Exhibit 5-19: The AquaSens Fluid Monitoring System ………………………………….. 5-33
Exhibit 5-20: The Dolphin II Hysteroscopic Fluid Management System …………… 5-34
Exhibit 5-21: The Aquilex Fluid Control System …………………………………………… 5-36
Exhibit 5-22: The Hysteroscopic Fluid Management System for
Hysteroscopic Morcellation…………………………………………………….. 5-38
Exhibit 5-23: The FluidSafe Fluid Management System………………………………… 5-40
6. U.S. BENIGN UTERINE CONDITIONS THERAPY SYSTEMS MARKET… 6-1
6.1 Global Endometrial Ablation Devices ………………………………………… 6-1
6.1.1 Market Forecast ………………………………………………………. 6-1
6.1.2 Competitive Analysis ………………………………………………… 6-3
6.2 Uterine Artery Embolization Systems ………………………………………… 6-4
6.2.1 Market Forecast ………………………………………………………. 6-4
6.2.2 Competitive Analysis ………………………………………………… 6-6
6.3 Hysteroscopes and Related Products ……………………………………….. 6-8
6.3.1 Market Forecast ………………………………………………………. 6-8
6.3.2 Competitive Analysis ………………………………………………. 6-12
6.3.3 Single-Insertion Hysteroscopic Morcellator Systems……. 6-12
6.3.3.1 Market Forecast ………………………………………. 6-14
6.3.3.2 Competitive Analysis ………………………………… 6-15
6.4 Combined Market Forecast ……………………………………………………. 6-15
Exhibit 6-1: Global Endometrial Ablation Devices, Market Forecast,
2012-2017 …………………………………………………………………………….. 6-2
Exhibit 6-2: 2012, Global Endometrial Ablation Device Market,
Share by Supplier…………………………………………………………………… 6-5
Exhibit 6-3: Uterine Artery Embolization Systems, Market Forecast,
2012-2017 …………………………………………………………………………….. 6-7
Exhibit 6-4: 2012, Uterine Artery Embolization Systems Market,
Share by Supplier…………………………………………………………………… 6-9
Exhibit 6-5: Hysteroscopes and Related Products, Market Forecast,
2012-2017 …………………………………………………………………………… 6-10
Exhibit 6-6: 2012, Hysteroscopes and Related Products Market,
Share by Supplier…………………………………………………………………. 6-13
Exhibit 6-7: Single-Insertion Hysteroscopic Morcellator Systems,
Market Forecast, 2012-2017 ………………………………………………….. 6-16
U.S. Benign Uterine Conditions Therapy Systems Market Table of Contents
2013 Elsevier Business Intelligence v #A470
Exhibit 6-8: 2012, Single-Insertion Hysteroscopic Morcellator Systems
Market, Share by Supplier……………………………………………………… 6-17
Exhibit 6-9: U.S. Benign Uterine Conditions Therapy Systems,
Combined Market Forecast, 2012-2017 …………………………………… 6-18
Exhibit 6-10: U.S. Benign Uterine Conditions Therapy Systems,
Market Forecast, by Product Segment, 2012-2017 ……………………. 6-21
Exhibit 6-11: 2012, U.S. Benign Uterine Conditions Therapy Systems Market,
Share of Sales, by Product Segment……………………………………….. 6-23
Exhibit 6-12: 2017, U.S. Benign Uterine Conditions Therapy Systems Market,
Share of Sales, by Product Segment……………………………………….. 6-24
7. COMPANY PROFILES…………………………………………………………………….. 7-1
7.1 Boston Scientific Corporation …………………………………………………… 7-1
7.2 CeloNova Biosciences, Inc………………………………………………………. 7-3
7.3 Hologic, Inc……………………………………………………………………………. 7-4
7.4 InSightec LTD/Elbit Imaging LTD ……………………………………………… 7-6
7.5 Johnson & Johnson………………………………………………………………… 7-8
7.6 Philips Healthcare/Royal Philips Electronics NV ……………………….. 7-11
7.7 Smith & Nephew PLC……………………………………………………………. 7-12
7.8 KARL STORZ GmbH & Co. KG………………………………………………. 7-14
APPENDIX: COMPANY LISTING